TL-532 First in Human
Several TLR3 ligands have been used in the clinic, providing early proof of concept of the therapeutic potential of this strategy. However, due to low reproducibility and complexity of manufacturing, no TLR3 ligands has reached the market yet.
Tollys has filled a patent claiming an entirely new family of TLR3 ligands (EP 18305561) in 2018.
New TLR3 ligands enables patient’s immune system
for personalized cancer immunotherapy.
41 quai Fulchiron
69005 Lyon, FRANCE
+33 (0)4 78 04 30 90